King Luther Capital Management Corp Purchases 793 Shares of McKesson Corporation $MCK

King Luther Capital Management Corp boosted its position in shares of McKesson Corporation (NYSE:MCK – Free Report) by 1.6% in the third quarter, HoldingsChannel.com reports. The fund owned 49,889 shares of the company’s stock after acquiring an additional 793 shares during the quarter. King Luther Capital Management Corp’s holdings in McKesson were worth $42,596,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MCK. Bingham Private Wealth LLC boosted its position in McKesson by 4.2% in the third quarter. Bingham Private Wealth LLC now owns 577 shares of the company’s stock valued at $493,000 after buying an additional 23 shares during the last quarter. Maryland State Retirement & Pension System raised its position in McKesson by 7.9% during the 3rd quarter. Maryland State Retirement & Pension System now owns 7,190 shares of the company’s stock worth $6,139,000 after buying an additional 527 shares during the last quarter. Ritholtz Wealth Management raised its position in McKesson by 6.3% during the 3rd quarter. Ritholtz Wealth Management now owns 14,918 shares of the company’s stock worth $12,737,000 after buying an additional 887 shares during the last quarter. UNIVEST FINANCIAL Corp raised its position in McKesson by 4.3% during the 3rd quarter. UNIVEST FINANCIAL Corp now owns 675 shares of the company’s stock worth $576,000 after buying an additional 28 shares during the last quarter. Finally, DSG Capital Advisors LLC raised its position in McKesson by 20.0% during the 3rd quarter. DSG Capital Advisors LLC now owns 4,134 shares of the company’s stock worth $3,530,000 after buying an additional 690 shares during the last quarter. Institutional investors and hedge funds own 85.07% of the company’s stock.

Insider Activity at McKesson

In related news, CAO B Jr sold 111 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total value of $98,950.95. Following the completion of the transaction, the chief accounting officer directly owned 521 shares of the company’s stock, valued at approximately $464,445.45. This represents a 17.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Francisco Fraga sold 650 shares of the stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $1,102.96, for a total transaction of $716,924.00. Following the completion of the sale, the executive vice president owned 4,414 shares of the company’s stock, valued at $4,868,465.44. This trade represents a 12.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 2,161 shares of company stock valued at $2,242,515 over the last quarter. 0.06% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. UBS Group lifted their price objective on shares of McKesson from $1,200.00 to $1,250.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Morgan Stanley set a $977.00 price objective on shares of McKesson in a research note on Tuesday, October 6th. Mizuho raised their target price on shares of McKesson from $905.00 to $1,020.00 and gave the stock a “neutral” rating in a report on Tuesday, October 20th. Weiss Ratings upgraded shares of McKesson from a “buy (b)” rating to a “buy (b+)” rating in a research report on Monday. Finally, TD Cowen boosted their target price on shares of McKesson from $1,006.00 to $1,200.00 and gave the company a “buy” rating in a research report on Thursday, November 5th. Fifteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,040.29.

View Our Latest Stock Analysis on MCK

Key Headlines Impacting McKesson

Investors following MCK have been watching these headlines:

McKesson Stock Down 0.2%

MCK stock opened at $1,080.76 on Thursday. The firm has a market cap of $124.79 billion, a P/E ratio of 27.79, a PEG ratio of 1.83 and a beta of 0.27. The company’s 50-day simple moving average is $948.83 and its 200-day simple moving average is $871.94. McKesson Corporation has a 52-week low of $723.68 and a 52-week high of $1,121.50.

McKesson (NYSE:MCK – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $11.68 EPS for the quarter, beating the consensus estimate of $10.72 by $0.96. McKesson had a negative return on equity of 202.94% and a net margin of 1.12%. The company had revenue of $110.96 billion for the quarter, compared to analyst estimates of $109.90 billion. During the same period last year, the company earned $9.86 earnings per share. McKesson’s quarterly revenue was up 7.5% compared to the same quarter last year. On average, analysts anticipate that McKesson Corporation will post 46.16 earnings per share for the current fiscal year.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Investors of record on Tuesday, December 1st will be issued a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, December 1st. McKesson’s payout ratio is presently 9.67%.

About McKesson

(Free Report)

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers. The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care. Founded in 1833, McKesson serves customers primarily in the United States and Canada.

Further Reading

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK – Free Report).

Institutional Ownership by Quarter for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.